Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cloti-Xa
- Development stage
- Phase 1
- Lead developer
- Venus Remedies
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Subcutaneous
01
Overview
**Cloti-Xa** is a biosimilar low molecular weight heparin (LMWH) containing **enoxaparin sodium**, developed by Venus Remedies Ltd for the prevention and treatment of venous thromboembolism. It is administered as a subcutaneous injection in various strengths (e.g., 40mg/0.4ml, 60mg/0.6ml, 300mg multidose) and functions as an anticoagulant by binding to antithrombin III, preferentially inhibiting **factor Xa** over **factor IIa** (thrombin), thereby preventing clot formation and progression. Bioequivalence to the reference product **Clexane** (Sanofi) has been demonstrated in pharmacodynamic studies measuring anti-Xa, anti-IIa activities, TFPI release, and aPTT, with similar safety profiles including risks of bleeding, injection site reactions, thrombocytopenia, and elevated liver enzymes. Primary indications include **deep vein thrombosis (DVT)**, **pulmonary embolism (PE)**, **acute coronary syndrome (ACS)**, and post-surgical prophylaxis.[1][2][3][10]
- Brand names
- Cloti-Xa
- Other names
- Cloti XA
02
Targets
Factor XIaATIII (Antithrombin III)FXIIa (Coagulation Factor XIIa)F10 (Factor Xa)Coagulation Factor IXaF2 (Thrombin)
Beyond the preview
Go deeper on Cloti-Xa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cloti-Xa.